// App-Quantinova.ai

3058 : Development of the Princess Margaret Immune Oncology Prognostic Index (PM-IPI): A novel prognostic score for patients (pts) treated in immune oncology (IO) phase I (P1) trials.

Researchers

Presenter

  • Daphne Day

Principal Investigators

  • Anthony M. Joshua

  • Lisa Wang

  • Albiruni R. Razak

  • Aaron Richard Hansen

  • Natasha B. Leighl

  • Marcus O. Butler

  • Anna Spreafico

  • Lillian L. Siu

  • Philippe L. Bedard

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Drug Development Program, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved